Changmeng Cai

This study validates BCL-2 as a therapeutic target in CRPC by showing its upregulation under AR inhibition and demonstrating efficacy of BCL-2 inhibitors in preclinical and clinical models.

This study shows that in prostate cancer with TMPRSS2:ERG fusion, androgen deprivation increases AKT activation, which may reduce the effectiveness of AR-targeted therapy, suggesting combination therapy could be beneficial.

This study shows that voluntary exercise reduces tumor growth in a mouse model of castration-resistant prostate cancer by affecting DNA replication, AR signaling, and mitochondrial dynamics.